Drug Profile
THV 01
Alternative Names: THV01; THV01-1; THV01-2Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator THERAVECTYS
- Class AIDS vaccines; Dendritic cell vaccines; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II HIV infections
Most Recent Events
- 27 Feb 2019 Theravectys completes a phase I/II trial in HIV infections in Belgium and France (NCT02054286) (EudraCT2011-006260-52)
- 01 Dec 2017 THV 01 is still in phase I/II trials for HIV infections (Theravectys website, December 2017)
- 03 Dec 2014 THERAVECTYS has patent protection for lentiviral vector technology in Europe